<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2011-0839</journal-id>
<journal-title><![CDATA[Universitas Medica]]></journal-title>
<abbrev-journal-title><![CDATA[Univ. Med.]]></abbrev-journal-title>
<issn>2011-0839</issn>
<publisher>
<publisher-name><![CDATA[Pontificia Universidad Javeriana]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2011-08392020000400129</article-id>
<article-id pub-id-type="doi">10.11144/javeriana.umed61-4.prof</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Profilaxis farmacológica de crisis epilépticas postraumáticas tempranas]]></article-title>
<article-title xml:lang="en"><![CDATA[Pharmacological Prophylaxis of Early Post-Traumatic Epileptic Seizures]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Siuffi-Campo]]></surname>
<given-names><![CDATA[Suad]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Herrera-Trujillo]]></surname>
<given-names><![CDATA[Alejandro]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Jiménez-Cardozo]]></surname>
<given-names><![CDATA[Natalia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Becerra-Hernández]]></surname>
<given-names><![CDATA[Lina Vanessa]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Pontificia Universidad Javeriana  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Centro Médico Imbanaco  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Pontificia Universidad Javeriana  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Pontificia Universidad Javeriana  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2020</year>
</pub-date>
<volume>61</volume>
<numero>4</numero>
<fpage>129</fpage>
<lpage>141</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S2011-08392020000400129&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S2011-08392020000400129&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S2011-08392020000400129&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen De acuerdo con la alta incidencia y prevalencia del trauma craneoencefálico (TCE) en Colombia y reconociendo la epilepsia como una de las secuelas más comunes posteriores al trauma, es importante conocer cuáles son los medicamentos con mayor efectividad clínica en la terapia profiláctica para su prevención. El objetivo de este artículo es llevar a cabo una revisión de tema según lo publicado en la literatura reciente. La búsqueda se realizó en bases de datos como PubMed y SciELO. Los fármacos de elección para las crisis epilépticas postraumáticas son los anticonvulsivantes. Se revisaron datos sobre la efectividad profiláctica de otros grupos farmacológicos sin resultados actuales que apoyen su uso en la clínica. Se concluyó que las crisis epilépticas son una de las complicaciones más frecuentes después de sufrir un TCE, y la literatura reporta que la terapia profiláctica es útil para prevenir crisis epilépticas tempranas; pero no hay consenso sobre la diferencia en cuanto a la efectividad entre fármacos anticonvulsivantes. El levetiracetam tiene evidencia a favor tanto por su efectividad como por su seguridad, por lo que debe estudiarse a profundidad, pues sería uno de los candidatos como fármaco antiepileptogénico.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract Taking into account the high incidence and prevalence of traumatic brain injury (TBI) in our environment and recognizing epilepsy as one of the most common sequelae after trauma, it is important to know which drugs have high clinical effectiveness in prophylactic therapy for prevention of it. The objective of this article is to carry out a Topic Review according to what has been published in the recent literature. The search was carried out in databases such as Pubmed and Scielo. It has been shown that the drugs of choice for post-traumatic epileptic seizures are anticonvulsants. Data on other pharmacological groups were reviewed. It was concluded that epileptic seizures continue to be one of the most frequent complications after suffering an episode of TBI, and the literature reports that prophylactic therapy is useful for the prevention of early epileptic seizures, but there is no clarity or consensus regarding the difference in effectiveness with use. Levetiracetam has evidence in favor, both for its effectiveness and for its safety, given its mechanism of action and should be studied in depth, as it would also be one of the candidates as an antiepileptogenic drug.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[traumatismos craneoencefálicos]]></kwd>
<kwd lng="es"><![CDATA[epilepsia postraumática]]></kwd>
<kwd lng="es"><![CDATA[crisis tempranas]]></kwd>
<kwd lng="es"><![CDATA[terapia farmacológica]]></kwd>
<kwd lng="es"><![CDATA[mecanismos de acción]]></kwd>
<kwd lng="es"><![CDATA[profilaxis]]></kwd>
<kwd lng="en"><![CDATA[craniocerebral trauma]]></kwd>
<kwd lng="en"><![CDATA[post-traumatic epilepsy]]></kwd>
<kwd lng="en"><![CDATA[early seizures]]></kwd>
<kwd lng="en"><![CDATA[pharmacological therapy]]></kwd>
<kwd lng="en"><![CDATA[pharmacological mechanisms]]></kwd>
<kwd lng="en"><![CDATA[prophylaxis]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Braga]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epilepsia post-traumática.]]></article-title>
<source><![CDATA[Rev Chil Epilepsia]]></source>
<year>2012</year>
<volume>12</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>85-92</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2.</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Henao]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Puerta]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Arcilla]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<source><![CDATA[Manejo prehospitalario del trauma craneoencefálico por accidente de tránsito en la ciudad de Medellín.]]></source>
<year>2008</year>
<publisher-loc><![CDATA[Medellín ]]></publisher-loc>
<publisher-name><![CDATA[Universidad CES]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B3">
<label>3.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Agustín Godoy]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Pahnke]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Piñero]]></surname>
<given-names><![CDATA[GR]]></given-names>
</name>
<name>
<surname><![CDATA[Videtta]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Aguilera]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cuidados intensivos en el trauma craneoencefálico grave.]]></article-title>
<source><![CDATA[Neurocienc Colomb]]></source>
<year>2016</year>
<volume>23</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>193-234</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maas]]></surname>
<given-names><![CDATA[AI]]></given-names>
</name>
<name>
<surname><![CDATA[Stocchetti]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Bullock]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Moderate and severe traumatic brain injury in adults.]]></article-title>
<source><![CDATA[Lancet Neurol.]]></source>
<year>2008</year>
<volume>7</volume>
<page-range>728-41</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gennarelli]]></surname>
<given-names><![CDATA[TA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mechanisms of brain injury.]]></article-title>
<source><![CDATA[J Emerg Med.]]></source>
<year>1993</year>
<volume>11</volume>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
<page-range>5-11</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Klein]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Tyrlikova]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevention of epilepsy: should we be avoiding clinical trials?]]></article-title>
<source><![CDATA[Epilepsy Behav.]]></source>
<year>2017</year>
<volume>72</volume>
<page-range>188-94</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Medina Marín]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Escobar Betancourth]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sistema glutamatérgico, primera parte: sinaptología, homeostasis y muerte celular.]]></article-title>
<source><![CDATA[Rev Colomb Psiquiatr]]></source>
<year>2002</year>
<volume>31</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>193-218</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bergles]]></surname>
<given-names><![CDATA[DE]]></given-names>
</name>
<name>
<surname><![CDATA[Diamond]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Jahr]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clearance of glutamate inside the synapse and beyond.]]></article-title>
<source><![CDATA[Curr Opin Neurobiol.]]></source>
<year>1999</year>
<volume>9</volume>
<page-range>29-38</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Prast]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Philippu]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Nitric oxide as a modulator of neuronal function.]]></article-title>
<source><![CDATA[Prog Neurob.]]></source>
<year>2001</year>
<volume>64</volume>
<page-range>51-68</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kiss]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Vizi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Nitric oxide: a novel link between synaptic and nonsynaptyc transmission.]]></article-title>
<source><![CDATA[Trends in Neurosc.]]></source>
<year>2001</year>
<volume>4</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>211-5</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11.</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sasaki]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Dawson]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Dawson]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The no signallingin thebrain.]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Reith]]></surname>
<given-names><![CDATA[MEA]]></given-names>
</name>
</person-group>
<source><![CDATA[Cerebral signal transduction: from first to fourth messengers.]]></source>
<year>2000</year>
<page-range>151-74</page-range><publisher-loc><![CDATA[Totowa ]]></publisher-loc>
<publisher-name><![CDATA[Humana Press]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B12">
<label>12.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barger]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Basile]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Activation of microglia by secreted amyloid precursor protein evokes release of glutamate by cystine exchange and attenuates synaptic function.]]></article-title>
<source><![CDATA[J Neurochem.]]></source>
<year>2001</year>
<volume>76</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>846-54</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13.</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pitkänen]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Bolkvadze]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Head Trauma and epilepsy.]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Noebels]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Avoli]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Rogawski]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<source><![CDATA[Jasper's basic mechanisms of the epilepsies]]></source>
<year>2012</year>
<edition>4th ed.</edition>
<publisher-loc><![CDATA[Bethesda (MD) ]]></publisher-loc>
<publisher-name><![CDATA[National Center for Biotechnology Information (US)]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B14">
<label>14.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hunt]]></surname>
<given-names><![CDATA[RFI]]></given-names>
</name>
<name>
<surname><![CDATA[Boychuk]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Smith]]></surname>
<given-names><![CDATA[BN]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Neural circuit mechanisms of post-traumatic epilepsy.]]></article-title>
<source><![CDATA[Front Cell Neurosci.]]></source>
<year>2013</year>
<volume>7</volume>
<page-range>89</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15.</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dudek]]></surname>
<given-names><![CDATA[FE]]></given-names>
</name>
<name>
<surname><![CDATA[Staley]]></surname>
<given-names><![CDATA[KJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The time course and circuit mechanisms of acquired epileptogenesis.]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Noebels]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Avoli]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Rogawski]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Olsen]]></surname>
<given-names><![CDATA[RW]]></given-names>
</name>
<name>
<surname><![CDATA[Delgado-Escueta]]></surname>
<given-names><![CDATA[AV]]></given-names>
</name>
</person-group>
<source><![CDATA[Jasper's basic mechanisms of the epilepsies.]]></source>
<year>2012</year>
<edition>4th ed.</edition>
<publisher-loc><![CDATA[Bethesda (MD) ]]></publisher-loc>
<publisher-name><![CDATA[National Center for Biotechnology Information (US)]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B16">
<label>16.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Riascos]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Buriticá]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Jiménez]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Castro]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Guzmán]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Palacios]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Neurodegenerative diversity in human cortical contusion: histological analysis of tissue derived from decompressive craniectomy.]]></article-title>
<source><![CDATA[Brain Res.]]></source>
<year>2013</year>
<volume>1537</volume>
<page-range>86-99</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17.</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Prince]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
<name>
<surname><![CDATA[Parada]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Graber]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Traumatic brain injury and posttraumatic epilepsy.]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Noebels]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Avoli]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Rogawski]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Olsen]]></surname>
<given-names><![CDATA[RW]]></given-names>
</name>
<name>
<surname><![CDATA[Delgado-Escueta]]></surname>
<given-names><![CDATA[AV]]></given-names>
</name>
</person-group>
<source><![CDATA[Jasper's basic mechanisms of the epilepsies.]]></source>
<year>2012</year>
<edition>4th ed.</edition>
<publisher-loc><![CDATA[Bethesda (MD ]]></publisher-loc>
<publisher-name><![CDATA[National Center for Biotechnology Information (US)]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B18">
<label>18.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Gu]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[He]]></surname>
<given-names><![CDATA[X-P]]></given-names>
</name>
<name>
<surname><![CDATA[Joshi]]></surname>
<given-names><![CDATA[RB]]></given-names>
</name>
<name>
<surname><![CDATA[Wackerle]]></surname>
<given-names><![CDATA[HD]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Transient inhibition of TrkB kinase after status epilepticus prevents development of temporal lobe epilepsy.]]></article-title>
<source><![CDATA[Neuron]]></source>
<year>2013</year>
<volume>79</volume>
<page-range>31-8</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McDaniel]]></surname>
<given-names><![CDATA[SS]]></given-names>
</name>
<name>
<surname><![CDATA[Wong]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Therapeutic role of mammalian target of rapamycin (mTOR) inhibition in preventing epileptogenesis.]]></article-title>
<source><![CDATA[Neurosci Lett.]]></source>
<year>2011</year>
<volume>497</volume>
<page-range>231-9</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Drexel]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Puhakka]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Kirchmair]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Hörtnagl]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Pitkänen]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Sperk]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Expression of GABA receptor subunits in the hippocampus and thalamus after experimental traumatic brain injury.]]></article-title>
<source><![CDATA[Neuropharmacology]]></source>
<year>2015</year>
<volume>88</volume>
<page-range>122-33</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21.</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[González]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Lopera]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Arango]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Manual de terapéutica.]]></article-title>
<source><![CDATA[Manual de terapéutica]]></source>
<year>2016</year>
<edition>17.a ed.</edition>
<publisher-loc><![CDATA[Medellín ]]></publisher-loc>
<publisher-name><![CDATA[Corporación para Investigaciones Biológicas]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B22">
<label>22.</label><nlm-citation citation-type="book">
<collab>Lexicomp</collab>
<source><![CDATA[Phenytoin: drug information]]></source>
<year></year>
<publisher-loc><![CDATA[Waltham, MA ]]></publisher-loc>
<publisher-name><![CDATA[UpToDate]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B23">
<label>23.</label><nlm-citation citation-type="book">
<collab>Lexicomp</collab>
<source><![CDATA[Valproate: drug information]]></source>
<year></year>
<publisher-loc><![CDATA[Waltham, MA ]]></publisher-loc>
<publisher-name><![CDATA[UpToDate]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B24">
<label>24.</label><nlm-citation citation-type="book">
<collab>Lexicomp</collab>
<source><![CDATA[Carbamazepine: drug information]]></source>
<year></year>
<publisher-loc><![CDATA[Waltham, MA ]]></publisher-loc>
<publisher-name><![CDATA[UpToDate]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B25">
<label>25.</label><nlm-citation citation-type="book">
<collab>Lexicomp</collab>
<source><![CDATA[Levetiracetam: drug information]]></source>
<year></year>
<publisher-loc><![CDATA[Waltham, MA ]]></publisher-loc>
<publisher-name><![CDATA[UpToDate Inc.]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B26">
<label>26.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Surges]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Volynski]]></surname>
<given-names><![CDATA[KE]]></given-names>
</name>
<name>
<surname><![CDATA[Walker]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Is levetiracetam different from other antiepileptic drugs? Levetiracetam and its cellular mechanism of action in epilepsy revisited.]]></article-title>
<source><![CDATA[Therc Adv Neurol Disord.]]></source>
<year>2008</year>
<volume>1</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>13-24</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jedrzejczak]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Kuncíková]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Magureanu]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[VIPe Study Group. An observational study of first-line valproate monotherapy in focal epilepsy.]]></article-title>
<source><![CDATA[Eur J Neurol.]]></source>
<year>2008</year>
<volume>15</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>66-72</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Khan]]></surname>
<given-names><![CDATA[NR]]></given-names>
</name>
<name>
<surname><![CDATA[Van Landingham]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Fierst]]></surname>
<given-names><![CDATA[TM]]></given-names>
</name>
<name>
<surname><![CDATA[Hymel]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Hoes]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Evans]]></surname>
<given-names><![CDATA[LT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Should levetiracetam or phenytoin be used for posttraumatic seizure prophylaxis? a systematic review of the literature and meta-analysis.]]></article-title>
<source><![CDATA[Neurosurgery]]></source>
<year>2016</year>
<volume>79</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>775-82</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jones]]></surname>
<given-names><![CDATA[KE]]></given-names>
</name>
<name>
<surname><![CDATA[Puccio]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Harshman]]></surname>
<given-names><![CDATA[KJ]]></given-names>
</name>
<name>
<surname><![CDATA[Falcione]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Benedict]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Jankowitz]]></surname>
<given-names><![CDATA[BT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Levetiracetam versus phenytoin for seizure prophylaxis in severe traumatic brain injury.]]></article-title>
<source><![CDATA[Neurosurg Focus.]]></source>
<year>2008</year>
<volume>25</volume>
<numero>4</numero>
<issue>4</issue>
</nlm-citation>
</ref>
<ref id="B30">
<label>30.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bratton]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
<name>
<surname><![CDATA[Chestnut]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
<name>
<surname><![CDATA[Ghajar]]></surname>
<given-names><![CDATA[J,]]></given-names>
</name>
<name>
<surname><![CDATA[McConnell Hammond]]></surname>
<given-names><![CDATA[FF]]></given-names>
</name>
<name>
<surname><![CDATA[Harris]]></surname>
<given-names><![CDATA[OA]]></given-names>
</name>
<name>
<surname><![CDATA[Hartl]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<collab>Brain Trauma Foundation</collab>
<collab>American Association of Neurological Surgeons</collab>
<collab>Congress of Neurological Surgeons</collab>
<collab>Joint Section on Neurotrauma and Critical Care</collab>
<collab>AANS/CNS</collab>
<article-title xml:lang=""><![CDATA[Guidelines for the management of severe traumatic brain injury. XIII. Antiseizure prophylaxis.]]></article-title>
<source><![CDATA[J Neurotrauma.]]></source>
<year>2007</year>
<volume>24</volume>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
<page-range>S83-6</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Temkin]]></surname>
<given-names><![CDATA[NR]]></given-names>
</name>
<name>
<surname><![CDATA[Dikmen]]></surname>
<given-names><![CDATA[SS]]></given-names>
</name>
<name>
<surname><![CDATA[Wilensky]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Keihm]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Chabal]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<collab>HR</collab>
<article-title xml:lang=""><![CDATA[A randomized, doubleblind study of phenytoin for the prevention of post-traumatic seizures.]]></article-title>
<source><![CDATA[N Engl J Med.]]></source>
<year>1990</year>
<volume>323</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>497-502</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kruer]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
<name>
<surname><![CDATA[Harris]]></surname>
<given-names><![CDATA[LH]]></given-names>
</name>
<name>
<surname><![CDATA[Goodwin]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Kornbluth]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Thomas]]></surname>
<given-names><![CDATA[KP]]></given-names>
</name>
<name>
<surname><![CDATA[Slater]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Changing trends in the use of seizure prophylaxis after traumatic brain injury: a shift from phenytoin to levetiracetam.]]></article-title>
<source><![CDATA[J Crit Care.]]></source>
<year>2013</year>
<volume>28</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>883</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zimmermann]]></surname>
<given-names><![CDATA[LL]]></given-names>
</name>
<name>
<surname><![CDATA[Martin]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
<name>
<surname><![CDATA[Girgis]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treatment options for posttraumatic epilepsy.]]></article-title>
<source><![CDATA[Curr Opin Neurol.]]></source>
<year>2017</year>
<volume>30</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>580-6</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wilson]]></surname>
<given-names><![CDATA[CD]]></given-names>
</name>
<name>
<surname><![CDATA[Burks]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
<name>
<surname><![CDATA[Rodgers]]></surname>
<given-names><![CDATA[RB]]></given-names>
</name>
<name>
<surname><![CDATA[Evans]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
<name>
<surname><![CDATA[Bakare]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Safavi-Abbasi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Early and late posttraumatic epilepsy in the setting of traumatic brain injury: a meta-analysis and review of antiepileptic management.]]></article-title>
<source><![CDATA[World Neurosurg.]]></source>
<year>2018</year>
<volume>110</volume>
</nlm-citation>
</ref>
<ref id="B35">
<label>35.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Carney]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Totten]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[O'Reilly]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Guidelines for the management of severe traumatic brain injury. 4th ed.]]></article-title>
<source><![CDATA[Neurosurgery]]></source>
<year>2017</year>
<volume>80</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>6-15</page-range></nlm-citation>
</ref>
<ref id="B36">
<label>36.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kaminski]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
<name>
<surname><![CDATA[Rogawski]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Klitgaard]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The potential of antiseizure drugs and agents that act on novel molecular targets as antiepileptogenic treatments.]]></article-title>
<source><![CDATA[Neurotherapeutics]]></source>
<year>2014</year>
<volume>11</volume>
<page-range>385-400</page-range></nlm-citation>
</ref>
<ref id="B37">
<label>37.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zou]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Brayer]]></surname>
<given-names><![CDATA[SW]]></given-names>
</name>
<name>
<surname><![CDATA[Hurwitz]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Niyonkuru]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Fowler]]></surname>
<given-names><![CDATA[LE]]></given-names>
</name>
<name>
<surname><![CDATA[Wagner]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Neuroprotective, neuroplastic, and neurobehavioral effects of daily treatment with levetiracetam in experimental traumatic brain injury.]]></article-title>
<source><![CDATA[Neurorehabil Neural Repair.]]></source>
<year>2013</year>
<volume>27</volume>
<page-range>878-88</page-range></nlm-citation>
</ref>
<ref id="B38">
<label>38.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shetty]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prospects of levetiracetam as a neuroprotective drug against status epilepticus, traumatic brain injury, and stroke.]]></article-title>
<source><![CDATA[Front Neurol.]]></source>
<year>2013</year>
<volume>4</volume>
<page-range>1-6</page-range></nlm-citation>
</ref>
<ref id="B39">
<label>39.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yan]]></surname>
<given-names><![CDATA[HD]]></given-names>
</name>
<name>
<surname><![CDATA[Ji-Qun]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Ishihara]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Nagayama]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Serikawa]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Sasa]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Separation of antiepileptogenic and antiseizure effects of levetiracetam in the spontaneously epileptic rat (SER).]]></article-title>
<source><![CDATA[Epilepsia]]></source>
<year>2005</year>
<volume>46</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1170-7</page-range></nlm-citation>
</ref>
<ref id="B40">
<label>40.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mazarati]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Baldwin]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Klitgaard]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treatment with levetiracetam during the latent period after experimental status epilepticus reduces chronic spontaneous recurrent seizures.]]></article-title>
<source><![CDATA[Epilepsia]]></source>
<year>2003</year>
<volume>44</volume>
<numero>^s9</numero>
<issue>^s9</issue>
<supplement>9</supplement>
<page-range>223</page-range></nlm-citation>
</ref>
<ref id="B41">
<label>41.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sugaya]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Maru]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Kudo]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Shibasaki]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Kato]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Levetiracetam suppresses development of spontaneous EEG seizures and aberrant neurogenesis following kainate-induced status epilepticus.]]></article-title>
<source><![CDATA[Brain Res.]]></source>
<year>2010</year>
<volume>1352</volume>
<page-range>187-99</page-range></nlm-citation>
</ref>
<ref id="B42">
<label>42.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Willmore]]></surname>
<given-names><![CDATA[LJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Post-traumatic epilepsy: cellular mechanisms and implications for treatment.]]></article-title>
<source><![CDATA[Epilepsia]]></source>
<year>1990</year>
<volume>31</volume>
<numero>^s3</numero>
<issue>^s3</issue>
<supplement>3</supplement>
<page-range>S67-73</page-range></nlm-citation>
</ref>
<ref id="B43">
<label>43.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gusakov]]></surname>
<given-names><![CDATA[IV]]></given-names>
</name>
<name>
<surname><![CDATA[Ivanenko]]></surname>
<given-names><![CDATA[AI]]></given-names>
</name>
<name>
<surname><![CDATA[Grantyn]]></surname>
<given-names><![CDATA[VA]]></given-names>
</name>
<name>
<surname><![CDATA[Laur]]></surname>
<given-names><![CDATA[OIu]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ne&#301;rofiziologicheskie i [Neurophysiologic and histopathologic correlates of the effect of deferoxamine on the formation of an epileptic focus during blood injection into the rat cerebral cortex]]]></article-title>
<source><![CDATA[Patol Fiziol Eksp Ter.]]></source>
<year>1993</year>
<numero>4</numero>
<issue>4</issue>
<page-range>4-6</page-range></nlm-citation>
</ref>
<ref id="B44">
<label>44.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Danbolt]]></surname>
<given-names><![CDATA[NC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Glutamate uptake.]]></article-title>
<source><![CDATA[Prog in Neurob.]]></source>
<year>2001</year>
<volume>65</volume>
<page-range>1-105</page-range></nlm-citation>
</ref>
<ref id="B45">
<label>45.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mishra]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Singh]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Mukherjee]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Sharma]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dehydroepiandrosterone's antiepileptic action in FeCl3-induced epileptogenesis involves upregulation of glutamate transporters.]]></article-title>
<source><![CDATA[Epilepsy Res.]]></source>
<year>2013</year>
<volume>106</volume>
<page-range>83-91</page-range></nlm-citation>
</ref>
<ref id="B46">
<label>46.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Goodrich]]></surname>
<given-names><![CDATA[GS]]></given-names>
</name>
<name>
<surname><![CDATA[Kabakov]]></surname>
<given-names><![CDATA[AY]]></given-names>
</name>
<name>
<surname><![CDATA[Hameed]]></surname>
<given-names><![CDATA[MQ]]></given-names>
</name>
<name>
<surname><![CDATA[Dhamne]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
<name>
<surname><![CDATA[Rosenberg]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
<name>
<surname><![CDATA[Rotenberg]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ceftriaxone treatment after traumatic brain injury restores expression of the glutamate transporter, GLT-1, reduces regional gliosis, and reduces post-traumatic seizures in the rat.]]></article-title>
<source><![CDATA[J Neurotrauma.]]></source>
<year>2013</year>
<volume>30</volume>
<page-range>1434-41</page-range></nlm-citation>
</ref>
<ref id="B47">
<label>47.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jung]]></surname>
<given-names><![CDATA[KH]]></given-names>
</name>
<name>
<surname><![CDATA[Chu]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[ST]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Sinn]]></surname>
<given-names><![CDATA[DI]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cyclooxygenase-2 inhibitor, celecoxib, inhibits the altered hippocampal neurogenesis with attenuation of spontaneous recurrent seizures following pilocarpine-induced status epilepticus.]]></article-title>
<source><![CDATA[Neurobiol Dis.]]></source>
<year>2006</year>
<volume>23</volume>
<page-range>237-46</page-range></nlm-citation>
</ref>
<ref id="B48">
<label>48.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bar-Klein]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Cacheaux]]></surname>
<given-names><![CDATA[LP]]></given-names>
</name>
<name>
<surname><![CDATA[Kamintsky]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Prager]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Weissberg]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Schoknecht]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Losartan prevents acquired epilepsy via TGF-&#946; signaling suppression.]]></article-title>
<source><![CDATA[Ann Neurol.]]></source>
<year>2014</year>
<volume>75</volume>
<page-range>864-75</page-range></nlm-citation>
</ref>
<ref id="B49">
<label>49.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gao]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Wei]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Jiang]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Fingolimod (FTY720) inhibits neuroinflammation and attenuates spontaneous convulsions in lithium-pilocarpine induced status epilepticus in rat model.]]></article-title>
<source><![CDATA[Pharmacol Biochem Behav.]]></source>
<year>2012</year>
<volume>103</volume>
<page-range>187-96</page-range></nlm-citation>
</ref>
<ref id="B50">
<label>50.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chu]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Jung]]></surname>
<given-names><![CDATA[KH]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[ST]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
<name>
<surname><![CDATA[Kang]]></surname>
<given-names><![CDATA[KM]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[HK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Erythropoietin reduces epileptogenic processes following status epilepticus.]]></article-title>
<source><![CDATA[Epilepsia]]></source>
<year>2008</year>
<volume>49</volume>
<page-range>1723-32</page-range></nlm-citation>
</ref>
<ref id="B51">
<label>51.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jung]]></surname>
<given-names><![CDATA[KH]]></given-names>
</name>
<name>
<surname><![CDATA[Chu]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[ST]]></given-names>
</name>
<name>
<surname><![CDATA[Park]]></surname>
<given-names><![CDATA[K Il]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
<name>
<surname><![CDATA[Kang]]></surname>
<given-names><![CDATA[KM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Molecular alterations underlying epileptogenesis after prolonged febrile seizure and modulation by erythropoietin.]]></article-title>
<source><![CDATA[Epilepsia]]></source>
<year>2011</year>
<volume>52</volume>
<page-range>541-50</page-range></nlm-citation>
</ref>
<ref id="B52">
<label>52.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sandsmark]]></surname>
<given-names><![CDATA[DK]]></given-names>
</name>
<name>
<surname><![CDATA[Pelletier]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Weber]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
<name>
<surname><![CDATA[Gutmann]]></surname>
<given-names><![CDATA[DH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mammalian target of rapamycin: master regulator of cell growth in the nervous system.]]></article-title>
<source><![CDATA[Histol Histopathol.]]></source>
<year>2007</year>
<volume>22</volume>
<page-range>895-903</page-range></nlm-citation>
</ref>
<ref id="B53">
<label>53.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Guo]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Zeng]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Brody]]></surname>
<given-names><![CDATA[DL]]></given-names>
</name>
<name>
<surname><![CDATA[Wong]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rapamycin attenuates the development of posttraumatic epilepsy in a mouse model of traumatic brain injury.]]></article-title>
<source><![CDATA[PLoS One.]]></source>
<year>2013</year>
<volume>8</volume>
<numero>5</numero>
<issue>5</issue>
</nlm-citation>
</ref>
<ref id="B54">
<label>54.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pitkänen]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Nehlig]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Brooks-Kayal]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
<name>
<surname><![CDATA[Dudek]]></surname>
<given-names><![CDATA[FE]]></given-names>
</name>
<name>
<surname><![CDATA[Friedman]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Galanopoulou]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Issues related to development of antiepileptogenic therapies.]]></article-title>
<source><![CDATA[Epilepsia]]></source>
<year>2013</year>
<volume>54</volume>
<numero>^s4</numero>
<issue>^s4</issue>
<supplement>4</supplement>
<page-range>35-43</page-range></nlm-citation>
</ref>
<ref id="B55">
<label>55.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[White]]></surname>
<given-names><![CDATA[HS]]></given-names>
</name>
<name>
<surname><![CDATA[Löscher]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Searching for the ideal antiepileptogenic agent in experimental models: single treatment versus combinatorial treatment strategies.]]></article-title>
<source><![CDATA[Neurotherapeutics]]></source>
<year>2014</year>
<volume>11</volume>
<page-range>373-84</page-range></nlm-citation>
</ref>
<ref id="B56">
<label>56.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Löscher]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Single versus combinatorial therapies in status epilepticus: novel data from preclinical models]]></article-title>
<source><![CDATA[Epilepsy Behav.]]></source>
<year>2015</year>
<volume>49</volume>
<page-range>20-5</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
